Alpha Teknova, Inc. · NASDAQ:TKNO
Alpha Teknova — Investor Presentation (August 2026)
36 slides from Alpha Teknova's investor presentation, August 2026
Slide 1: Making Solutions Possible
Making Solutions Possible COMPANY OVERVIEW August 2026
Slide 2: Forward-looking statements and use of non-GAAP financial measures
Forward-looking statements and use of non-GAAP financial measures Statements in this presentation about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, b
Slide 3: We Make Solutions Possible
WE MAKE SOLUTIONS POSSIBLE Leading provider of critical reagents for the discovery, development, and commercialization of novel therapies and diagnostics 2026E REVENUE 2026E REVENUE GROWTH PROJECT ADJUSTED GUIDANCE (MIDPOINT) EBITDA POSITIVE QTR IN $45-47M 14% 2027 ACTIVE CLINICAL CUSTOMER NUMBER OF
Slide 4: Our products are fundamental to the life sciences industry
Our products are fundamental to the life sciences industry LIQUID MICROBIAL MOLECULAR AGAR PLATES CULTURE MEDIA BIOLOGY REAGENTS AND SUPPLEMENTS Extensive selection of standard Wide variety of liquid media Vast range of product types, sizes, and specialty pre-poured agar and broths to expand a parti
Slide 5: Primary End Markets
2025 REVENUE BREAKDOWN Primary End Markets 5% Non- Product Revenue APPROX. APPROX. APPROX. 1,000 400 1,900 ACCOUNTS ~15% ACCOUNTS ACCOUNTS Other Markets BIOPHARMA AND LIFE SCIENCE TOOLS OTHER MARKETS CONTRACT AND DIAGNOSTICS MANUFACTURING ~50% Biopharma & • ~850 Biotech • ~250 Life Science Tools • A
Slide 6: Revenue by Product Type and Customer End Market
Revenue by Product Type and Customer End Market OTHER Total 2024 Revenue by Product~5% Type and End Market 2025 REVENUE BREAKDOWN CLINICAL • Lab Essentials: ~75% of 2025 Revenue SOLUTIONS Research-grade reagents (RUO) ~20% 15% CLINICAL Catalog product revenue comprises ~80% SOLUTIONS Catalog CUS
Slide 7: Why We Win
Why We Win CATALOG BUSINESS FASTER AS A FOUNDATION SMALLER CUSTOM TURNAROUND TIME BATCH SIZES Relative Annual Spend Initial Build Sizes for Custom Time from Order to Shipment by Account Type in 2025 Research and Clinical Orders for Custom Orders 44X 10,000 L MONTHS QC 1,000 L Typical batch size for
Slide 8: Build-Tek Custom Configurator
NEW AI-POWERED ASSISTANT Build●TekTM Custom Configurator Build complex custom product requests in minutes with Teknova’s interactive reagent assistant 3 minutes 3 days 30 years Build a complete Submit your Proven custom custom order with configuration and our reagent manufacturing just a few clicks
Slide 9: The barriers to producing custom GMP-grade reagents is considerable
The barriers to producing custom GMP-grade reagents for our target markets is considerable FAVORABLE COST STRUCTURE FASTER TURNAROUND TIMES FOR SMALL BATCH SIZES FROM MODULAR MANUFACTURING • Dynamic Capacity • Switch seamlessly between production of Increased number of inventory and on-demand produc
Slide 10: Key Takeaways
Key Takeaways Research- Significant Critical grade operating Additional supplier of reagents leverage in near-term GMP-grade provide a our P&L catalysts reagents diverse, as our create for emerging predictable, revenue potential therapies and and growing increases tailwinds diagnostics foundation ©
Slide 11: Continued success in attracting clinical customers
Continued success in attracting clinical customers NUMBER OF CLINICAL SOLUTIONS CUSTOMERS1 60 10 48 6 34 6 35% 24 21 50 3 42 5 13 28 3 22 17 2020-2025 10 CAGR 2020 2021 2022 2023 2024 2025 Biopharma Tools/Dx/Other Total Customer is defined as any customer purchasing within the fiscal year. There is
Slide 12: We are a critical supplier for more than 70 therapies in clinical trials
We are a critical supplier for more than 70 therapies in clinical trials ~$3.0M ~$0.3M 29.8X 3.2X ~$0.2M ~$0.1M Illustrative Annual and Relative 1X 1.4X Customer Spend by Phase1 CLINICAL DEVELOPMENT RESEARCH PRECLINICAL POST-APPROVAL AND DISCOVERY DEVELOPMENT PHASE Stage of Clinical Therapies Suppor
Slide 13: Life Science Tools and Diagnostics accounts comprise remaining Clinical Solutions customers
Life Science Tools and Diagnostics accounts comprise remaining Clinical Solutions customers These customers utilize Teknova to manufacture their proprietary formulations for resale or as raw materials in their manufacturing processes to support high growth end markets such as bioprocessing and liqui
Slide 14: Key Takeaways
Key Takeaways Research- Significant Critical grade operating Additional supplier of reagents leverage in near-term GMP-grade provide a our P&L catalysts reagents diverse, as our create for emerging predictable, revenue potential therapies and and growing increases tailwinds diagnostics foundation ©
Slide 15: Supporting 3,000+ customers across the life sciences
Supporting 3,000+ customers across the life sciences Limited Customer Concentration Stable Top Accounts (Top Lab Essentials Revenue / Total Revenue) 2025 2019-25 CAGR End Market Tenure Rank (Pre-COVID) 1 Genomics >10 yrs 45% Top 5: 12% 2 Genomics >10 yrs 42% Top 10: 18% 3 Genomics 9 yrs 72% 4 Large
Slide 16: Our products are fundamental to the life sciences industry
Our products are fundamental to the life sciences industry Plasmid Production Gene Synthesis DNA and RNA We support the leading life science tools companies: • Genetic Sequencing • Single Cell Analysis Spatial- genomics Enzyme Production • Spatial Genomics • Enzyme Production • Nucleic Acid Producti
Slide 17: History of consistent double-digit growth
History of consistent double-digit growth LAB ESSENTIALS REVENUE $35,000,000 $30,000,000 $25,000,000 $20,000,000 $15,000,000 $10,000,000 11% 2008-2025 $5,000,000 CAGR $- 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Pandemic © 2026 Alpha Teknova, Inc. ● Al
Slide 18: Key Takeaways
Key Takeaways Research- Significant Critical grade operating Additional supplier of reagents leverage in near-term GMP-grade provide a our P&L catalysts reagents diverse, as our create for emerging predictable, revenue potential therapies and and growing increases tailwinds diagnostics foundation ©
Slide 19: Over $200M in revenue capacity with limited additional capital investment required
Over $200M in revenue capacity with limited additional capital investment required • ISO 13485-certified (GMP) facilities to support customers from discovery to commercialization • Over 180,000 ft2 of facilities including approximately 10,000 ft2 of ISO 7 cleanrooms • In-house automation, engineerin
Slide 20: Effective cost management sets up attractive financial profile with top-line growth
Effective cost management after period of investment sets up attractive financial profile with top-line growth $45 300 $41 $41 $35 $37 $38 250 $25 200 MILLIONS ($) $15 FTEs (#) 150 ADJUSTED EBITDA $5 POSITIVE BY END OF 2027 100 ($5) ($7) ($15) 50 ($15) ($20) ($22) ($25) 0 2022 2023 2024 2025 Revenue
Slide 21: 70% of revenue growth drops to bottom line
SIGNIFICANT OPERATING LEVERAGE WITH TOP-LINE GROWTH 70% of revenue growth drops to bottom line 65%+ Gross Margin Gross Profit Variable Cost of Goods Sold • Grows in proportion to revenue – direct materials, packaging, scrap/waste, supplies, etc. 55-60% • ~25-30% of total cost of sales today Gross Ma
Slide 22: Key Takeaways
Key Takeaways Research- Significant Critical grade operating Additional supplier of reagents leverage in near-term GMP-grade provide a our P&L catalysts reagents diverse, as our create for emerging predictable, revenue potential therapies and and growing increases tailwinds diagnostics foundation ©
Slide 23: Investing in commercial capabilities and activities
NEAR-TERM CATALYST Investing in commercial capabilities and activities SITUATION INVESTMENT ($2M) • We believe Biopharma end 1. Expansion of field team with expertise in life markets have stabilized and science tools, diagnostics, and large pharma higher funding levels will persist 2. Drive more bra
Slide 24: Historically seen a four-quarter lag between funding changes and effects on revenue
NEAR-TERM CATALYST Historically seen a four-quarter lag between funding changes and effects on revenue 45 6 40 4-QUARTER SHIFT SITUATION 5 35 • Biotech funding was down from mid- 30 4 2022 to mid-2025 • Strong rebound in funding observed 25 starting in Q4:2025 20 3 • 2026 off to a strong start 15 2
Slide 25: Plan to expand portfolio through commercial collaborations and M&A
NEAR-TERM CATALYST Plan to expand portfolio through commercial collaborations and M&A Specific areas of interest: • Cell culture media and supplements • Cytokines, growth factors, enzymes, antibodies and other proteins • Geographic expansion © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● August
Slide 26: Proven management team with extensive experience in life sciences
Proven management team with extensive experience in life sciences Stephen Gunstream Matt Lowell Damon Terrill Jennifer Henry President & Chief Executive Officer Chief Financial Officer General Counsel, Senior Vice President, Chief Compliance Officer Marketing Neil Abhyankar Rakesh Ahuja Bella Neufel
Slide 27: Leading provider of custom research and GMP-grade reagents ready to support customers as they scale
Leading provider of custom research and GMP-grade reagents ready to support our customers as they scale We are successfully executing on our long-term growth plan, having increased our Clinical Solutions customer base from 13 to 60 over the past five years1 We believe we are poised to drive signific
Slide 28: Q2:26 Financials
teknova: Q2:26 Financials
Slide 29: Q2:2026 Revenue Highlights
Q2:2026 Revenue Highlights Revenue by Category ($M) KEY HIGHLIGHTS $12.2 • Total first quarter revenue up 18% compared to the same period in $10.3 18% y/y $2.4 prior year $2.1 • Lab Essentials increased 18% compared to the same period in prior year • Clinical Solutions increased 18% $9.2 compared to
Slide 30: Q2:2026 Income Statement Highlights
Q2:2026 Income Statement Highlights Gross Margin (%) Total OpEx ($M) $7.4 $7.8 38.7% 40.1% Q2:2025 Q2:2026 Q2:2025 Q2:2026 Adjusted EBITDA1 ($M) Diluted EPS ($) ($0.7) ($0.06) ($0.8) ($0.07) Q2:2025 Q2:2026 Q2:2025 Q2:2026 1 Adjusted EBITDA is non-GAAP and adds back stock-based compensation and any
Slide 31: Q2:2026 Cash Flow and Balance Sheet Highlights
Q2:2026 Cash Flow and Balance Sheet Highlights Capital Expenditure ($M) Free Cash Flow1 ($M) ($0.6) ($2.3) $0.2 $0.1 Q2:2025 Q2:2026 Q2:2025 Q2:2026 Cash, Cash Equivalents, and Short-Term Investment was $17.4M as of June 30, 2026 1 Free Cash Flow equals cash provided by (used in) operating activitie
Slide 32: Quarterly Financial Trends
Quarterly Financial Trends Gross Margin1 (%) Total OpEx ($M) $10.2 $7.9 $7.8 $8.0 $7.9 $8.1 $7.8 $7.5 $7.4 $7.2 39% 40% 31% 32% 34% 29% 30% 31% $8.9 24% 23% $7.8 $7.5 $7.8 $8.0 $7.4 $7.2 $7.4 $8.1 $7.8 Q1:24 Q2:24 Q3:24 Q4:24 Q1:25 Q2:25 Q3:25 Q4:25 Q1:26 Q2:26 Q1:24 Q2:24 Q3:24 Q4:24 Q1:25 Q2:25 Q3
Slide 33: 2026 Outlook and Capital Runway
2026 Outlook and Capital Runway GUIDANCE • Raising fiscal 2026 outlook for revenue and improving outlook for Free Cash Outflow • Anticipate total revenue of $45 million to $47 million for fiscal year ending December 31, 2026 (“2026”), up 14% y/y at the midpoint • Targeting Free Cash Outflow of less
Slide 34: Supplemental Non-GAAP Reconciliations
Supplemental Non-GAAP Reconciliations
Slide 35: Non-GAAP Reconciliations
Non-GAAP Reconciliations ALPHA TEKNOVA, INC. Reconciliation of Non-GAAP Measures to the Most Comparable GAAP Measures (unaudited) (in thousands) © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● August 2026 35
Slide 36: Teknova
teknova: